Matching articles for "methylphenidate"
Issue 1736 · September 1, 2025
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD…

Med Lett Drugs Ther. 2025 Sep 1; 67(1736):137-44 doi:10.58347/tml.2025.1736a
Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD has been associated with reduced risks of substance abuse, criminal behavior, unintentional injuries, serious traffic accidents, and all-cause mortality. Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Issue 1735 · August 18, 2025 Free
In Brief: New Warning for Extended-Release Stimulants for ADHD

The FDA now requires that the labels of all extendedelease stimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) include a warning about the risks of weight loss and other adverse…

Med Lett Drugs Ther. 2025 Aug 18; 67(1735):135-6 doi:10.58347/tml.2025.1735f
The FDA now requires that the labels of all extendedelease stimulants used for treatment of attention-deficit/hyperactivity disorder (ADHD) include a warning about the risks of weight loss and other adverse effects associated with their use in children <6 years old. The labels of all stimulants used for treatment of ADHD already contain a boxed warning about the high risk of abuse and dependence associated with their use.
Issue 1718 · December 23, 2024
Clonidine Oral Suspension (Onyda XR) for ADHD

The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha 2- adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):205-6 doi:10.58347/tml.2024.1718d
The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha 2- adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥6 years old. Clonidine ER tablets have been available for years for treatment of ADHD in children 6-17 years old.
Issue 1669 · February 6, 2023
Transdermal Dextroamphetamine (Xelstrym) for ADHD

The FDA has approved a dextroamphetamine transdermal patch ( Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first…

Med Lett Drugs Ther. 2023 Feb 6; 65(1669):22-4 doi:10.58347/tml.2023.1669d
The FDA has approved a dextroamphetamine transdermal patch ( Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first transdermal amphetamine product to be approved in the US. A methylphenidate transdermal patch (Daytrana, and generics) has been available for years for treatment of ADHD.
Issue 1664 · November 28, 2022 Free
In Brief: Alternatives to Adderall

The short-acting formulation of mixed amphetamine salts ( Adderall , and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):191-2
The short-acting formulation of mixed amphetamine salts ( Adderall , and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in the US. Until an adequate supply is restored, patients may be looking for alternatives.
Issue 1640 · December 27, 2021
Xywav - A Mixed-Salt Oxybate Oral Solution for Idiopathic Hypersomnia

Xywav (Jazz), an oral solution that contains calcium, magnesium, potassium, and sodium oxybates, has been approved by the FDA for treatment of idiopathic hypersomnia in adults. It is the first drug to be…

Med Lett Drugs Ther. 2021 Dec 27; 63(1640):207-8
Xywav (Jazz), an oral solution that contains calcium, magnesium, potassium, and sodium oxybates, has been approved by the FDA for treatment of idiopathic hypersomnia in adults. It is the first drug to be approved in the US for this indication. Xywav was approved in 2020 for treatment of excessive daytime sleepiness or cataplexy in patients ≥7 years old with narcolepsy. It contains about 92% less sodium than sodium oxybate oral solution (Xyrem) , which has been available in the US for years for use in patients ≥7 years old with narcolepsy.
Issue 1634 · October 4, 2021
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD

The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate ( Azstarys – Corium) for once-daily treatment of…

Med Lett Drugs Ther. 2021 Oct 4; 63(1634):157-9
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate ( Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
Issue 1617 · February 8, 2021
Pitolisant (Wakix) for Narcolepsy

The FDA has approved pitolisant ( Wakix – Harmony), a histamine-3 (H 3 )-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is…

Med Lett Drugs Ther. 2021 Feb 8; 63(1617):19-21
The FDA has approved pitolisant ( Wakix – Harmony), a histamine-3 (H 3 )-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H 3 -receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Issue 1590 · January 27, 2020
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in…

Med Lett Drugs Ther. 2020 Jan 27; 62(1590):9-15
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior.4-6 Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Issue 1579 · August 26, 2019
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness

The FDA has approved solriamfetol ( Sunosi – Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with…

Med Lett Drugs Ther. 2019 Aug 26; 61(1579):132-4
The FDA has approved solriamfetol ( Sunosi – Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Pitolisant (Wakix) , an H3-receptor antagonist/inverse agonist recently approved by the FDA for treatment of excessive daytime sleepiness in patients with narcolepsy, will be reviewed in a future issue.
Issue 1578 · August 12, 2019
Jornay PM - Evening-Dosed Methylphenidate for ADHD

The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit…

Med Lett Drugs Ther. 2019 Aug 12; 61(1578):126-8
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning.
Issue 1549 · June 18, 2018
A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)

The FDA has approved an extended-release oral suspension formulation of amphetamine ( Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):e106-8
The FDA has approved an extended-release oral suspension formulation of amphetamine ( Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same extended-release amphetamine product is available as an orally disintegrating tablet and is marketed as Adzenys XR-ODT . Another extended-release oral suspension formulation of amphetamine, Dyanavel XR , was approved earlier.
Issue 1544 · April 9, 2018
Opioids for Pain

Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations…

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):57-64
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Issue 1497 · June 20, 2016
Two New Amphetamines for ADHD

Two new extended-release amphetamine products have been approved by the FDA for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old: Adzenys XR-ODT (Neos…

Med Lett Drugs Ther. 2016 Jun 20; 58(1497):80-1
Two new extended-release amphetamine products have been approved by the FDA for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old: Adzenys XR-ODT (Neos Therapeutics), an orally distintegrating tablet, and Dyanavel XR (Tris Pharma), an oral suspension.
Issue 1495 · May 23, 2016
QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets

The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate ( QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first…

Med Lett Drugs Ther. 2016 May 23; 58(1495):68-9
The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate ( QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first long-acting chewable formulation of the drug to be marketed in the US. Immediate-release chewable methylphenidate tablets ( Methylin , and generics) have been available since 2003.
Issue 1478 · September 28, 2015
Racemic Amphetamine Sulfate (Evekeo) for ADHD

The FDA has approved racemic amphetamine sulfate ( Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of…

Med Lett Drugs Ther. 2015 Sep 28; 57(1478):137-8
The FDA has approved racemic amphetamine sulfate ( Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of narcolepsy in patients ≥6 years old and for short-term treatment of obesity in patients ≥12 years old.
Issue 1473 · July 20, 2015
Aptensio XR - Another Long-Acting Methylphenidate for ADHD

The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain…

Med Lett Drugs Ther. 2015 Jul 20; 57(1473):101-3
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Issue 1464 · March 16, 2015
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into…

Med Lett Drugs Ther. 2015 Mar 16; 57(1464):37-40
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into adulthood. A recent study in a large Danish cohort found that ADHD was associated with increased mortality in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD has been reported to lower the risk of serious traffic accidents and criminal behavior.
Issue 1409 · February 4, 2013
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate

The FDA has approved a once-daily, extended-release oral suspension of methylphenidate ( Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid…

Med Lett Drugs Ther. 2013 Feb 4; 55(1409):10-1
The FDA has approved a once-daily, extended-release oral suspension of methylphenidate ( Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid formulation of the drug to be marketed for once-daily use. A short-acting oral solution ( Methylin , and generics) has been available since 2003.
Issue 105 · May 1, 2011
Drugs for Treatment of ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.

Treat Guidel Med Lett. 2011 May; 9(105):23-8
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.
Issue 1357 · February 7, 2011
Another Extended-Release Alpha2-Agonist for ADHD

The FDA has approved an extended-release formulation of clonidine hydrochloride ( Kapvay – Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the…

Med Lett Drugs Ther. 2011 Feb 7; 53(1357):10-2
The FDA has approved an extended-release formulation of clonidine hydrochloride ( Kapvay – Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second alpha 2 -adrenergic agonist approved for this indication; guanfacine hydrochloride (Intuniv) was the first, but only clonidine is approved for use with stimulants.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1308 · March 23, 2009
Focalin XR for ADHD

Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children…

Med Lett Drugs Ther. 2009 Mar 23; 51(1308):22-4
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 51 · November 1, 2006
Drugs for Treatment of ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by…

Treat Guidel Med Lett. 2006 Nov; 4(51):77-82
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by a persistent pattern of frequent, severe inattention and/or hyperactivity/impulsivity that starts before the age of 7, is present in 2 or more settings (such as home and school), causes significant impairment in function, and is not caused by another mental disorder. The drugs approved for treatment of ADHD by the FDA are listed in this article. Except for atomoxetine, they are all stimulants and are classified as controlled substances by the US Drug Enforcement Administration (DEA).
Issue 1237 · June 19, 2006
Transdermal Methylphenidates (Daytrana) for ADHD

A transdermal patch formulation of methylphenidate ( Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like…

Med Lett Drugs Ther. 2006 Jun 19; 48(1237):49-51
A transdermal patch formulation of methylphenidate ( Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Issue 1227 · January 30, 2006
A New Indication for Gamma Hydroxybutyrate (Xyrem) in Narcolepsy

Gamma hydroxybutyrate (GHB), a central-nervous-system depressant notorious for its use in "date rape", was approved by the FDA in 2002 as sodium oxybate ( Xyrem - Jazz Pharmaceuticals) for oral treatment of…

Med Lett Drugs Ther. 2006 Jan 30; 48(1227):11-2
Gamma hydroxybutyrate (GHB), a central-nervous-system depressant notorious for its use in "date rape", was approved by the FDA in 2002 as sodium oxybate ( Xyrem - Jazz Pharmaceuticals) for oral treatment of cataplexy in patients with narcolepsy. Now it has also been approved for treatment of excessive daytime sleepiness (EDS) in these patients. Xyrem is a Schedule III controlled substance.
Issue 1205 · March 28, 2005 Free
In Brief: Adderall

On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994;…

Med Lett Drugs Ther. 2005 Mar 28; 47(1205):28
On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994; 36:109) . The immediate-release form of Adderall was never marketed in Canada. The withdrawal was based on 20 reports internationally of sudden death in patients taking the drug. These deaths, 14 of them in children, were not linked to overdose or abuse. The FDA decided that the number of sudden deaths was no greater than expected among the large number of people taking the drug, but because 5 of the children who died had structural heart defects, added a warning against using the drug in such patients. There is no evidence that Adderall offers any advantage over methylphenidate ( Ritalin , and others) or dextroamphetamine ( Dexedrine, and others), but some patients who do not respond satisfactorily to these drugs may respond to Adderall . Medical Letter consultants see no need to discontinue Adderall in patients who are taking it and doing well. For patients with a heart defect or a family history of sudden unexpected cardiovascular death, methylphenidate might be a better choice.
Issue 1189 · August 16, 2004
Atomoxetine (Strattera) Revisited

Atomoxetine ( Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that…

Med Lett Drugs Ther. 2004 Aug 16; 46(1189):65
Atomoxetine ( Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time, The Medical Letter concluded that it was unclear whether atomoxetine was as effective as stimulants such as methylphenidate ( Concerta , and others) ( Medical Letter 2003; 45:11 ). Since then, the drug has been heavily advertised directly to the public for use in both children and adults.
Issue 1159 · June 23, 2003
Prilosec, Nexium and Stereoisomers

Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram…

Med Lett Drugs Ther. 2003 Jun 23; 45(1159):51-2
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Issue 1149 · February 3, 2003
Atomoxetine (Strattera) for ADHD

Atomoxetine ( Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is…

Med Lett Drugs Ther. 2003 Feb 3; 45(1149):11-2
Atomoxetine ( Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not a controlled substance and is approved for use in adults as well as children. Older non-stimulant drugs that have been used to treat ADHD, although not FDA-approved, include the alpha 2 -agonist clonidine ( Catapres , and others) and the tricyclic antidepressant desipramine ( Norpramin , and others) (Medical Letter 1996; 38:109).
Issue 1145 · December 9, 2002
Gamma Hydroxybutyrate (Xyrem) for Narcolepsy

The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB),…

Med Lett Drugs Ther. 2002 Dec 9; 44(1145):103-5
The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB), a metabolite of gamma-aminobutyric acid (GABA), is a central-nervous-system depressant marketed in Europe for use in general anesthesia. In recent years it has been notorious for its use in "date-rape" ( Medical Letter 2002; 44:21 ). Xyrem is a Schedule III controlled substance.
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1130 · May 13, 2002
Dexmethylphenidate (Focalin) For ADHD

Dexmethylphenidate ( Focalin - Novartis), a new formulation of methylphenidate ( Ritalin , and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is…

Med Lett Drugs Ther. 2002 May 13; 44(1130):45-6
Dexmethylphenidate ( Focalin - Novartis), a new formulation of methylphenidate ( Ritalin , and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the d-threo-enantiomer of racemic methylphenidate. "Now the right half may be all your patients need," said a recent ad. Focalin is the third new methylphenidate formulation marketed in the last two years.
Issue 1086 · September 4, 2000
A New Long-acting Methylphenidate (Concerta)

Methylphenidate ( Ritalin , and others) is now available in a new extended-release formulation ( Concerta --Alza) for treatment of attention deficit/hyperactivity disorder (ADHD).

Med Lett Drugs Ther. 2000 Sep 4; 42(1086):80-1
Methylphenidate ( Ritalin , and others) is now available in a new extended-release formulation ( Concerta --Alza) for treatment of attention deficit/hyperactivity disorder (ADHD).
Issue 1049 · March 26, 1999
Modafinil for Narcolepsy

Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated…

Med Lett Drugs Ther. 1999 Mar 26; 41(1049):30-1
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated with narcolepsy.
Issue 1033 · August 14, 1998
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually…

Med Lett Drugs Ther. 1998 Aug 14; 40(1033):79-84
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain.
Issue 989 · December 6, 1996
Clonidine for Treatment of Attention-Deficit/Hyperactivity Disorder

Clonidine, an Alpha2-selective adrenergic agonist marketed in the USA only for treatment of hypertension, has also been used in recent years to treat children with attention-deficit/hyperactivity disorder…

Med Lett Drugs Ther. 1996 Dec 6; 38(989):109-10
Clonidine, an Alpha2-selective adrenergic agonist marketed in the USA only for treatment of hypertension, has also been used in recent years to treat children with attention-deficit/hyperactivity disorder (ADHD).
Issue 974 · May 10, 1996
Acute Reactions to Drugs of Abuse

Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them…

Med Lett Drugs Ther. 1996 May 10; 38(974):43-6
Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them have been reported.
Issue 936 · November 25, 1994
Adderall and Other Drugs for Attention-Deficit/Hyperactivity Disorder

A drug that combines the neutral sulfate salts of dextroamphetamine and racemic amphetamine with the dextro isomer of amphetamine saccharate and d,l amphetamine aspartate ( Adderall - Richwood Pharmaceutical)…

Med Lett Drugs Ther. 1994 Nov 25; 36(936):109-10
A drug that combines the neutral sulfate salts of dextroamphetamine and racemic amphetamine with the dextro isomer of amphetamine saccharate and d,l amphetamine aspartate ( Adderall - Richwood Pharmaceutical) has recently been promoted for treatment of children with Attention-Deficit/Hyperactivity Disorder (ADHD). This same mixture of amphetamine salts was previously marketed as Obetrol for treatment of obesity.
Issue 887 · January 8, 1993
Drugs for Pain

Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as…

Med Lett Drugs Ther. 1993 Jan 8; 35(887):1-6
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use , 3rd ed, Skokie, illinois: American pain society, 1992).
Issue 828 · October 5, 1990
Acute Reactions to Drugs of Abuse
Med Lett Drugs Ther. 1990 Oct 5; 32(828):92-4
Issue 819 · June 1, 1990
Sudden Death in children A Tricyclic Antidepressant

The 1990 labeling for Norpramin, the Merrell Dow brand of the tricyclic antidepressant desipramine, reports the occurrence of sudden death in an eight-year-old child treated with the drug. Desipramine is also…

Med Lett Drugs Ther. 1990 Jun 1; 32(819):53
The 1990 labeling for Norpramin, the Merrell Dow brand of the tricyclic antidepressant desipramine, reports the occurrence of sudden death in an eight-year-old child treated with the drug. Desipramine is also available as Pertofrane (Rorer) and generically.
Issue 765 · May 6, 1988
Methylphenidate Revisited

Methylphenidate ( Ritalin and others), a Schedule II controlled substance in the USA, is a short-acting central-nervous-system stimulant widely used for treatment of children with school performance or…

Med Lett Drugs Ther. 1988 May 6; 30(765):51-2
Methylphenidate ( Ritalin and others), a Schedule II controlled substance in the USA, is a short-acting central-nervous-system stimulant widely used for treatment of children with school performance or behavior problems, or what is now called Attention Deficit-Hyperactivity Disorder, or AD-HD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders , third ed., revised [DSM-III R], Washington, DC:authors, 1987, p 50). Some studies have estimated that more than 3% of elementary school students are taking methylphenidate, and one parents' group has brought a lawsuit against the American Psychiatric Association alleging that the drug is overused and has caused permanent damage to children (Wall St Journal, January 15, 1988, p 21).